Objectives: The availability of of Nano second laser open the door for physical treatment of melasma and other benign pigmentation disorder. recently the picosecond laser promise faster result than Nanosecond laser.
Introduction: Melasma is an acquired pigmentary disorder characterized by brownish hyperpigmented macules, usually on the face. This condition often affects those living in the tropical zone due to the high UV exposure in the area. Other benign hyperpigmentation disorders such as solar lentigines and ephelides are also commonly found in the area.
Materials / method: Currently, there is no permanent cure for melasma. In many Asian patients, these conditions are often unresponsive to topical medications. Nanosecond laser is not the first-line treatment in melasma, given its unpredictable results and risk of delay guttate hypopigmentation, which may be permanent.
In treating other benign pigmentation disorders, post-inflammatory hyperpigmentation is a common complication in the tropical zone. Pre-laser skin conditioning and post-laser skin care are essential to mitigate this risk.
Results: Treatment of melasma using low-fluence nanosecond laser toning has been very popular among Asian for many years. However, many treatments are required, the recurrence rate is high, and there is a risk of delayed guttate hypopigmentation. Besides melasma, nanosecond laser has also been widely used to treat other benign pigmentation disorders, albeit with a risk of post-inflammatory hyperpigmentation. The advent of picosecond laser, which can emit energy at a much shorter time, leading to a more photoacoustic than photothermal effects, may increase the efficacy with a higher safety profile.
Conclusion: Picosecond laser can do everything a nanosecond laser can with fewer treatments, less discomfort, but at a much higher cost.
Declaraciones
¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No
¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No
¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No
¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No
Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.